<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128930</url>
  </required_header>
  <id_info>
    <org_study_id>S62965</org_study_id>
    <nct_id>NCT04128930</nct_id>
  </id_info>
  <brief_title>Ambulatory CPAP Titration in Moderate Obstructive Sleep Apnea</brief_title>
  <acronym>ATMOS</acronym>
  <official_title>Ambulatory CPAP Titration in Moderate Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to compare two different ways of CPAP titration:

      CAP titration with fixed pressure vs. auto-titrating CPAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous positive airway pressure (CPAP) for the treatment of moderate obstructive sleep
      apnea (OSA) is only reimbursed in Belgium after in-laboratory overnight titration.
      Nevertheless, in a recent clinical practice guideline of the AASM, it is recommended that PAP
      therapy can be initiated using either in-laboratory titration or auto-titrating CPAP (APAP)
      at home in OSA patients without significant comorbidities. Indeed, several studies evaluated
      the impact of titration with APAP at home in these patients and showed that the outcome is
      comparable with in-hospital titration. Up to now, evidence for home titration with fixed CPAP
      (and follow-up via telemonitoring) is very limited. The use of sleep laboratory space is
      costly and limits access for diagnostic studies. This study aims to evaluate whether CPAP
      titration at home with fixed CPAP produces outcomes equal to those following APAP titration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CPAP adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Usage of the device (mean number of hours/day)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effective pressure level</measure>
    <time_frame>2 weeks</time_frame>
    <description>Optimal pressure of CPAP therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual apnea/hypopnea index</measure>
    <time_frame>2 weeks</time_frame>
    <description>Residual respiratory events during treatment with optimal CPAP pressure during PSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mask leaks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Objective leaks (L/min) during CPAP treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of good titration</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of patients with residual AHI &lt; 10 (objectivated with PSG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual device AHI</measure>
    <time_frame>3 months</time_frame>
    <description>Residual AHI as determined from device data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Daytime sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>3 months</time_frame>
    <description>PSQI questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 questionnaire score</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital contacts</measure>
    <time_frame>3 months</time_frame>
    <description>Number of contacts with the hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Fixed CPAP titration at home</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:
After 3 nights: median obstructive AHI&lt;5/h: decrease pressure with 2 cmH2O; median obstructive AHI&gt;5/h: increase with 2cmH2O
After 7 nights: median obstructive AHI&gt;5/h of 4 nights after last adaptation: increase with 2 cmH2O</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APAP titration at home</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAP titration at home</intervention_name>
    <description>Fixed CPAP or APAP titration at home</description>
    <arm_group_label>APAP titration at home</arm_group_label>
    <arm_group_label>Fixed CPAP titration at home</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate OSA (obstructive AHI 15-30/u on initial PSG)

        Exclusion Criteria:

          -  Presence of hypoventilation

          -  Presence of central sleep apnea (central AHI â‰¥ 15)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dries Testelmans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dries Testelmans, MD, PhD</last_name>
    <phone>00 32 16 342522</phone>
    <email>dries.testelmans@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dries Testelmans, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

